Tema Etfs LLC Acquires Shares of 89,529 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Tema Etfs LLC bought a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 89,529 shares of the company's stock, valued at approximately $1,102,000. Tema Etfs LLC owned 0.18% of Mineralys Therapeutics as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Mineralys Therapeutics by 5.0% during the 4th quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company's stock valued at $17,628,000 after purchasing an additional 68,811 shares in the last quarter. Millennium Management LLC grew its stake in shares of Mineralys Therapeutics by 1,015.8% during the fourth quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock valued at $13,562,000 after purchasing an additional 1,002,941 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Mineralys Therapeutics by 55.4% in the fourth quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock valued at $13,319,000 after purchasing an additional 385,726 shares in the last quarter. Caligan Partners LP raised its position in Mineralys Therapeutics by 3.1% in the 4th quarter. Caligan Partners LP now owns 1,011,155 shares of the company's stock worth $12,447,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Integral Health Asset Management LLC boosted its position in Mineralys Therapeutics by 145.8% in the 4th quarter. Integral Health Asset Management LLC now owns 875,000 shares of the company's stock valued at $10,771,000 after buying an additional 519,000 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday. Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the stock a "buy" rating in a report on Wednesday, May 14th. The Goldman Sachs Group reduced their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th.

Insider Transactions at Mineralys Therapeutics

In other news, Director Ra Capital Management, L.P. bought 1,296,296 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average cost of $13.50 per share, with a total value of $17,499,996.00. Following the completion of the purchase, the director now owns 4,280,051 shares of the company's stock, valued at $57,780,688.50. This represents a 43.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a total transaction of $129,729.42. Following the completion of the sale, the chief financial officer now owns 215,340 shares of the company's stock, valued at approximately $2,597,000.40. This represents a 4.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,579 shares of company stock valued at $1,534,353 in the last ninety days. 25.56% of the stock is currently owned by corporate insiders.

Mineralys Therapeutics Trading Up 0.4%

Shares of NASDAQ:MLYS traded up $0.07 during midday trading on Friday, hitting $16.39. The company had a trading volume of 117,974 shares, compared to its average volume of 480,742. The firm has a fifty day simple moving average of $14.48 and a 200 day simple moving average of $12.55. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -4.48 and a beta of -0.30. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.23. Equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.